Search PubMed⌕ Search

Biomedical subjects

Y Hirano

Publications and source records attributed to Y Hirano.

At least 271 records · Page 15Linked to original sources
PubMed1985

[Recent advances in mammographic diagnosis with respect to its technical aspects].

Technological advance has made remarkable improvements in image quality in the field of X-ray mammography which ensure to successful management of breast cancer in Japan. We convince simple mammographic technique is the state of arts in early detection of the curable breast cancer, however, attempts for further progress with respect to technology and its medical applications should be performed. Our fundamental and clinical works on this theme were presented here.

Breast Neoplasms↗
PubMed1984

Circus-movement tachycardia in frog atrium monitored by voltage-sensitive dyes.

Circus-movement tachycardia was studied using voltage-sensitive merocyanine-rhodanine dyes (dye XVII and NK2761). Excitatory waves were optically measured simultaneously from eight different regions of a ring of tissue formed from frog atrium. Application of acetylcholine in Ca2+-free solution (10(-10)-10(-9) g/ml) shortened the duration of optical action signals to cause nonuniform change in optical signal durations in about 60% of the preparations. Circus-movement tachycardia was produced by proper reduction and regional nonuniformity of optical signal durations. Under these circumstances it is easy to evoke circus-movement tachycardia by giving an extra stimulus to the site that shows a difference in optical signal durations.

Acetylcholine↗
PubMed1984

Effect of spironolactone on fluid volumes and adrenal steroids in primary aldosteronism.

Plasma volume (PV) and extracellular fluid volume (ECF) were determined in 7 patients with essential hypertension (controls) and in 10 patients with primary aldosteronism, while on a high Na diet (342 mEq/day) and on a low Na diet (12 mEq/day). The volume studies were repeated in 6 of the primary aldosteronism patients during treatment with spironolactone for over 3 months. Plasma renin activity (PRA), plasma aldosterone concentration (PAC), cortisol concentration, and serum Na and K concentrations were measured in all patients while on a Na-restricted diet (85 mEq/day) as well as on high-Na and low-Na diets. There were no significant changes in arterial pressure during different Na diets in any groups of patients with essential hypertension, or primary aldosteronism with and without spironolactone therapy. Spironolactone treatment normalized the arterial pressure in patients with primary aldosteronism at all Na intakes. These patients had greater values for PV and ECF than did those with essential hypertension. Spironolactone treatment reduced PV during the low-Na diet, but did not alter it during the high-Na diet. Spironolactone did not produce significant changes in ECF during either the high-Na or low-Na diets. Although there were no changes in PV and ECF in patients with primary aldosteronism due to changes in Na intake, both PV and ECF were significantly less in these patients during spironolactone treatment and in patients with essential hypertension during low-Na intake than during high-Na intake. With primary aldosteronism, PRA was depressed and PAC was elevated when compared to essential hypertension, these were not altered by different Na diets in the patients with primary aldosteronism as they were in those with essential hypertension. During treatment with spironolactone the PRA was restored to normal and showed normal changes with variations in dietary Na, but PAC remained elevated during spironolactone. Plasma cortisol was the same among those with essential hypertension and patients with untreated and spironolactone-treated primary aldosteronism. Serum K was less in untreated primary aldosteronism during all Na diets than in essential hypertension, but during spironolactone it was restored to normal. These results suggest that in primary aldosteronism the reduction in arterial pressure by spironolactone treatment does not occur simply by reductions in body fluid volumes. The long-term treatment of patients with primary aldosteronism with spironolactone does not inhibit the production of aldosterone, possibly because of enhanced activity of the renin-angiotensin system and an increase in serum K.

Adrenal Cortex Hormones↗
PubMed1984

Clinical effects of proteinase, sfericase (AI-794), on chronic bronchitis and similar diseases.

The clinical effect and utility of sfericase was compared with an inactive placebo by a double-blind method in three groups of a total 109 patients suffering from chronic respiratory diseases who had complained of difficult expectoration of sputum. A significantly greater improvement of expectoration was obtained in Group A-1 (6 tablets/day). Also in group A-1, more cases showed subjective and objective improvement, i.e., improvement in expectoration, reduction in coughs, decrease in the amount of sputum, and disappearance of râles. However, the sputum and its degree of purulency remained unchanged in most cases in all three groups. Side effects were few. The clinical efficacy of sfericase in the group with 2 tablets, 3X/day (total daily dose of 6 tablets) was shown to be significantly superior to the other two groups. This dosage was established as the optimal dose for treating difficulty in expectoration.

Adult↗
PubMed1984

[Clinical experience with cefoxitin in the surgical field].

Cefoxitin (CFX) was administered to 49 hospitalized patients in the surgical field, and the following results were obtained: Clinical results of the 12 patients with surgical infections were excellent in 1 patient, good in 10, and poor in 1, with the efficacy rate of 91.7%. CFX was also administered to 37 patients for prophylaxis of postoperative infections, and the clinical efficacy rate was 91.7%. No side effects were seen besides mild eruption in 1 patient. The above results indicate that CFX is exceeding useful in surgical field.

Adolescent↗
PubMed1983

A quantitative analysis of cell surface glycosphingolipid with a fluorescence activated cell sorter.

The fluorescence activated cell sorter (FACS) was used with an indirect membrane immunofluorescence technique to detect antibody against the Forssman antigen, a glycosphingolipid. Sheep erythrocytes, which contain Forssman antigen as a major membrane glycosphingolipid, were used as the target antigen. Detection of the anti-Forssman antibody on the sheep erythrocytes was done with specific fluorescein-conjugated second antibody and analyzed on a FACS. Compared to other available methods, analysis with the FACS was simple, sensitive, reproducible and quantitative. More than 250 pg of antibody could be detected. In addition, as little as 1 ng of Forssman antigen could be estimated by a binding inhibition experiment.

Animals↗